Hemogenyx Pharmaceuticals Share Price (HEMO)

2.95 +0.20 (+7.27%) delayed: 7:30AM BST
Bid price 2.70 Open price 2.97
Ask price 3.20 Prev close 2.95
High price 3.37 Spread 15.63%
Low price 2.77 Volume 1,129,971

Register now for FREE live Hemogenyx Pharmaceuticals share prices, Hemogenyx Pharmaceuticals stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Hemogenyx Pharmaceuticals Level 2 Data, indepth research tools and investor commentary for Hemogenyx Pharmaceuticals (HEMO) and other London Stock Exchange equities.

Hemogenyx Pharmaceuticals Share Price Chart

Advanced Charts >>

Register now for FREE Hemogenyx Pharmaceuticals share price charts

Hemogenyx Pharmaceuticals Share Price Information

Name Hemogenyx Pharmaceuticals Epic HEMO
Sector Nonequity Investment Instruments ISIN GB00BYX3WZ24
Activites Hemogenyx Pharmaceuticals plc (formerly Silver Falcon plc) is a preclinical-stage biotechnology company focused on the discovery, development and commercialisation of novel therapies and treatments for blood diseases, like leukemia and lymphoma. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. HemoGenyx's two distinct and complementary products include an immunotherapy product for patient conditioning, the CDX bi-specific antibody, and a cell therapy product for BM/HSC transplantation, the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care. Index n/a

Hemogenyx Pharmaceuticals Key Numbers

Latest Share Price (p) 2.95 Net Gearing (%) -67.32
Market Capitalisation (£m) 9.90 Gross Gearing (%) 11.02
Shares in issue (m) 360.02 Debt Ratio 0.00
P/E Ratio -2.75 Debt-to-Equity Ratio 0.00
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.12
Dividend Yield (%) 0.00 Price to book value 4.65
Dividend cover (x) 0.00 ROCE (%) -110.28
Earning per share (p) -1.00 EPS Growth (%) -25.00
52 week high / low 6.75 / 2.10 DPS Growth (%) n/a

Hemogenyx Pharmaceuticals Director Deals

Dec.Date Type Director Pos No. of Shares
12/02/2018 BUY Adrian Beeston RES 200,000
07/02/2018 BUY Dr Vladislav Sandler CEO 26,800
11/10/2017 BUY Adrian Beeston RES 400,000
10/10/2017 BUY Adrian Beeston RES 317,683
10/10/2017 BUY Peter Redmond NED 155,000

More Hemogenyx Pharmaceuticals Director Deals >>

Hemogenyx Pharmaceuticals Company News

09:47 19/10/2018

Hemogenyx's subsidiary Immugenyx inks pact with Orgenesis

Hemogenyx Pharmaceuticals said Friday its subsidiary Immugenyx had entered into a collaboration agreement with Orgenesis to develop the company's advanced hematopoietic chimeras. Immugenyx said it would collaborate with Orgenesis on the further development and commercialization of the company's...

07:00 19/10/2018

Collaboration, License and Investment by Orgenesis

RNS Number : 5429E Hemogenyx Pharmaceuticals PLC 19 October 2018   Hemogenyx Pharmaceuticals plc   ("Hemogenyx" or the "Company")   Collaboration, License and Investment by Orgenesis for unique mouse model   Hemogenyx Pharmaceuticals plc (LSE:...

07:00 15/10/2018

Collaboration with Johnson & Johnson Innovation

RNS Number : 9667D Hemogenyx Pharmaceuticals PLC 15 October 2018   Hemogenyx Pharmaceuticals Plc   ("Hemogenyx" or the "Company")   Immugenyx Enters Collaboration with Johnson & Johnson Innovation   Hemogenyx Pharmaceuticals Plc (LSE: HEMO;...

More Hemogenyx Pharmaceuticals Company News >>

Register now for FREE Hemogenyx Pharmaceuticals company news

Hemogenyx Pharmaceuticals Share Price Discussions

No Hemogenyx Pharmaceuticals Share Price Discussions

Register now for FREE Hemogenyx Pharmaceuticals share price discussions